Melbourne IVF invests a great deal of time and resources into clinical research to ensure we give our patients access to the most advanced science in fertility investigation and treatment. We are proud of our leadership within the fertility profession, and our clinicians, nurses and scientists are all committed to the future of fertility treatment. Following is an overview of some of our current research. If you would like to find out more about any of these projects, then please Contact Us.
Evaluating the protective effect of a GnRH agonist on ovarian function in young women with non-Hodgkin's lymphoma receiving R-CHOP-14
This randomised controlled trial will aim to assess whether GnRH-agonist given during the time of a fixed chemotherapy protocol for Non-Hodgkin's Lymphoma can protect ovarian function and potential fertility. This trial is designed so that half the women will receive the chemotherapy with the oral contraceptive pill and the other half will receive the chemotherapy with the oral contraceptive pill and the GnRH-a. Assessment will consist of blood tests, bone density tests and ultrasound over 5 years.
Autotransplantation of cryopreserved ovarian tissue
The aims of this project are to restore fertility and the opportunity for pregnancy with their own gametes, to patients at risk of chemotherapy/radiotherapy/surgically-induced ovarian failure and to restore ovarian endocrinological function.
The Fertility Preservation Service National (Australian and New Zealand) Database
The development of a national database is being proposed to provide comprehensive, relevant and accurate information on the fertility protection and preservation strategies for young women and men who otherwise risk permanent sterilisation from their cancer treatment. This database will also collect information on outcomes of the various techniques and allow Australian fertility specialists to remain at the forefront of fertility preservation techniques.
The LIGHT study: Assessing the effect of recombinant human growth hormone (r-hGH) on live birth rates in women who are poor responders undergoing an IVF/ICSI cycle
The aim of this Australian multi-centre collaborative study is to determine the influence of growth hormone treatment as an adjunct to stimulation with the maximal dose of FSH stimulation in the unexpected poor responding IVF patient - patients requiring maximal dose of stimulation despite being under 41 years of age. This is a randomised, double blind placebo controlled study.
Find out more about research projects across the Virtus Health Group.
